Nektar criticizes Pfizer's exit of Exubera pact
Pfizer took a $2.8-billion charge for dropping diabetes drug Exubera, but its conduct in exiting the biotech partnership could cost the firm far more.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.